Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Anebulo Pharmaceuticals Inc (NQ: ANEB )

1.530 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Anebulo Pharmaceuticals Inc

< Previous 1 2 Next >
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Lifecore Biomedical Announces Cooperation Agreement with 22NW
Provides for the Addition of 22NW Nominees Jason Aryeh and Matthew Korenberg, as Well as Humberto Antunes and Paul Johnson, to the Board 
From Lifecore Biomedical, Inc.
Via GlobeNewswire
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Announces New CEO
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 Extension
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Announces $6.6 Million Private Placement Financing
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals to Webcast R&D Day on September 26, 2022
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Highlights Recent Business Progress
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals to Host Inaugural R&D Day in New York City on Monday, September 26
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of a Phase 2 Clinical Trial and Provides Guidance on IND Submission
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2022 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Appoints Scott L. Anderson as Head of Investor Relations and Public Relations
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.